LZAGY News and Press, Lonza Group AG ADR From 10/30/22

Summary No disclosure in Q3, but positive news ahead. Capacity constraint will positively impact Lonza's earnings. The CMDO industry almost totally offset raw material inflationary pressure, we reiterate our positive key takeaways, confirming our buy rating target. ...

The Seeking Alpha Quant system has its quirks, but it is a great tool to find great holdings. I typically dredge through the weeds to find unique situations that may be unloved by the quant system. However, here are five strong buys that I agree with right now. Optimizin...

Lonza sports a solid set of numbers with a compelling valuation compared to its peers. The company has positive secular trends. There's a distraction over a contract termination, but positive fundamentals. Our most devoted readers know that at the Mare Lab we have a swee...

Lonza Group AG (LZAGY) Q2 2022 Earnings Conference Call July 22, 2022 8:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Daniel Buchta - ZKB Matthew Weston - Credit Suisse Vineet Agrawal ...

The following slide deck was published by Lonza Group AG in conjunction with their 2022 Q2 earnings call. For further details see: Lonza Group AG 2022 Q2 - Results - Earnings Call Presentation

Lonza Group AG press release ( OTCPK:LZAGY ): 1H Non-GAAP EPS of CHF 7.28. Revenue of CHF 2.98B (+17.3% Y/Y). Lonza reconfirms Outlook for Full-Year 2022 : Low to mid-teens CER sales growth; CORE EBITDA margin improvement in line with mid-term guidance. Lonza ...

Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence? Seres has had two share...

Lonza is the largest pure-play CDMO in the world. While pharmaceuticals and biotechs need to spend on risky R&D, Lonza just works on large-scale manufacturing. Perhaps Lonza will become the TSMC of outsourced therapy manufacturing, and the premium valuation will hold. Fo...

Lonza (OTCPK:LZAGY) (OTCPK:LZAGF) completed laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site in Nansha, China. The company said the expansion , which grew the laboratory footprint to 250 square meters, focused on extending the capacity of development...

Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million. Net loss of $50.00 million in Q4 compared with $18.3 million in Q4 2020, due significantly to preparing for launch of SER-109. Key publication on SER-109 C.difficile results and signs remain goo...